Table 3.
Shifts∗ in treatment class during the study in CSU patients (full analysis set).
| No shift |
sgAH |
sgAHUP |
fgAH |
CsA |
MONT |
OMA |
Other |
SGC |
No drug |
|
|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| sgAH (m = 136) | 31 (22.8) | 49 (36.0) | 25 (18.4) | 11 (8.1) | 1 (0.7) | 10 (7.4) | 18 (13.2) | 41 (30.1) | 6 (4.4) | 57 (41.9) |
| sgAHUP (m = 112) | 41 (36.6) | 24 (21.4) | 21 (18.8) | 6 (5.4) | 1 (0.9) | 8 (7.1) | 21 (18.8) | 22 (19.6) | 6 (5.4) | 33 (29.5) |
| fgAH (m = 74) | 17 (23.0) | 28 (37.8) | 17 (23.0) | 14 (18.9) | 0 | 3 (4.1) | 10 (13.5) | 27 (36.5) | 10 (13.5) | 34 (45.9) |
| CsA (m = 9) | 1 (11.1) | 3 (33.3) | 1 (11.1) | 1 (11.1) | 2 (22.2) | 0 | 5 (55.6) | 3 (33.3) | 1 (11.1) | 1 (11.1) |
| MONT (m = 36) | 12 (33.3) | 9 (25.0) | 6 (16.7) | 0 | 1 (2.8) | 3 (8.3) | 5 (13.9) | 13 (36.1) | 2 (5.6) | 9 (25.0) |
| OMA (m = 213) | 101 (47.4) | 31 (14.6) | 36 (16.9) | 11 (5.2) | 10 (4.7) | 2 (0.9) | 46 (21.6) | 23 (10.8) | 7 (3.3) | 52 (24.4) |
| OTHER (m = 275) | 92 (33.5) | 69 (25.1) | 50 (18.2) | 13 (4.7) | 9 (3.3) | 6 (2.2) | 29 (10.5) | 43 (15.6) | 21 (7.6) | 121 (44.0) |
| SGC (m = 45) | 11 (24.4) | 13 (28.9) | 9 (20.0) | 7 (15.6) | 1 (2.2) | 3 (6.7) | 8 (17.8) | 16 (35.6) | 8 (17.8) | 12 (26.7) |
| NO DRUG (m = 1) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (100) | 0 | 0 | 0 |
CsA, cyclosporine; fgAH, first-generation H1-antihistamine; MONT, montelukast; OMA, omalizumab; sgAH, second-generation H1-antihistamine (approved dose); sgAHUP, second-generation H1-antihistamine (up-dosed); SGC, systemic glucocorticosteroids. ∗Shift defined as a shift from one treatment class to another; patient may: a) Contribute to >1 shift across a row; b) Change from one treatment class to another, including back to the former treatment class. Percentages (%) are based on the number of patients in the full analysis set in each respective Baseline treatment class (m) for each respective group of interest